All In Biotech

Drug Trial Radar · NCT03313596

Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC

Multicenter Randomized Controlled Trial of Adenovirus-mediated Adjuvant Gene Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: Feb 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

180

Planned (sponsor's estimate)

Start

Mar 2013

Primary completion

Dec 2019

Study completion Dec 2019

Sponsor

Lead sponsor
Huazhong University of Science and TechnologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beijing YouAn Hospital
First posted
Oct 18, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Compare the effect of liver transplantation (LT) plus ADV-TK gene therapy versus LT only in advanced primary hepatocellular carcinoma.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • ADV-TkDrug

    The first ADV-TK dose was administered during the operation; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into peritoneum tissues around the liver. The second and third ADV-TK dose was administered 60 days and 90 days after LT; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into the celiac artery (60 mL) and the superior mesenteric artery (40 mL) via femoral-artery puncture.

  • LTProcedure

    Orthotopic LT and subsequent immunosuppression therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival, PFSTime frame: 2-year

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • 301 Military Hospital

    Beijing, China · Recruiting

  • General Hospital of Chinese People's Armed Police

    Beijing, China · Recruiting

  • The Third XiangYa Hospital of Central South University

    Changsha, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, China · Recruiting

  • The Third Affiliated Hospital,Sun Yat-sen University

    Guangzhou, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University

    Hangzhou, China · Recruiting

  • Zhongshan Hospital of Fudan University

    Shanghai, China · Recruiting

  • The First Affiliated Hospital of China Medical University

    Shenyang, China · Recruiting

  • The First Center Hospital of Tianjin

    Tianjin, China · Recruiting

  • The First Hospital of Xinjiang Medical University

    Ürümqi, China · Recruiting

  • Beijing Youan Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.